Inflammatory Response to DNA Damage (Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage)
Source: https://www.niehs.nih.gov/research/atniehs/labs/crb/studies/closed-studies/p53
Archived: 2026-04-23 17:15
Inflammatory Response to DNA Damage (Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage) | National Institute of Environmental Health Sciences
Skip Navigation
Inflammatory Response to DNA Damage (Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage)
Close the left navigation
Add
Study Background
This study is no longer accepting participants.
To find studies that are currently recruiting, please visit the
Join an
NIEHS Study
website
For More Information
ClinicalTrials.gov
NIH Clinical Studies
The gene p53 suppresses cancer and inflammation in the body, and NIEHS investigators speculate that changes in p53 lead to changes in inflammation and the ability to repair DNA damage. This study wants blood samples from participants to find out how the changes in p53 lead to these conditions.
Research has shown that certain proteins in cells may be linked to higher risk of developing inflammation, tumors, and other medical problems. By examining how the blood cells of healthy volunteers respond to environmental exposures, researchers hope to better understand the relationship of genes, environmental factors, and human diseases.
Eligibility Criteria
All participants must be currently enrolled in the EPR: DNA & Your Environment Study
Male or female 18 Years and older
Participants must be able to understand and provide written informed consent to participate in the study
Participants must be able to travel to the CRU
Nonpregnant
Healthy participants as defined by the International Red Cross guidelines (Healthy means that an individual feels well and can perform normal activities. If the individual has a chronic condition such as diabetes or high blood pressure, healthy also means that they are being treated and the condition is under control).
Participants with health outcomes identified by genotype-phenotype association studies.
HIV-1 seropositive under medicament treatment (for HIV P53 and TLR8 groups only) (checked every 6 months at visit)
Principal Investigator
Daniel Menendez Rendon, Ph.D.
Staff Scientist
Tel 984-287-4105
Fax 919-541-7593
[email protected]
Back
to Top
Last Reviewed: December 30, 2025
Skip Navigation
Inflammatory Response to DNA Damage (Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage)
Close the left navigation
Add
Study Background
This study is no longer accepting participants.
To find studies that are currently recruiting, please visit the
Join an
NIEHS Study
website
For More Information
ClinicalTrials.gov
NIH Clinical Studies
The gene p53 suppresses cancer and inflammation in the body, and NIEHS investigators speculate that changes in p53 lead to changes in inflammation and the ability to repair DNA damage. This study wants blood samples from participants to find out how the changes in p53 lead to these conditions.
Research has shown that certain proteins in cells may be linked to higher risk of developing inflammation, tumors, and other medical problems. By examining how the blood cells of healthy volunteers respond to environmental exposures, researchers hope to better understand the relationship of genes, environmental factors, and human diseases.
Eligibility Criteria
All participants must be currently enrolled in the EPR: DNA & Your Environment Study
Male or female 18 Years and older
Participants must be able to understand and provide written informed consent to participate in the study
Participants must be able to travel to the CRU
Nonpregnant
Healthy participants as defined by the International Red Cross guidelines (Healthy means that an individual feels well and can perform normal activities. If the individual has a chronic condition such as diabetes or high blood pressure, healthy also means that they are being treated and the condition is under control).
Participants with health outcomes identified by genotype-phenotype association studies.
HIV-1 seropositive under medicament treatment (for HIV P53 and TLR8 groups only) (checked every 6 months at visit)
Principal Investigator
Daniel Menendez Rendon, Ph.D.
Staff Scientist
Tel 984-287-4105
Fax 919-541-7593
[email protected]
Back
to Top
Last Reviewed: December 30, 2025